Subscribe to our Newsletters !!
Drug quality is defined not only how a drug is man
Eppendorf is launching the new VisioNize® box 2,
The journey and merging of sperm and egg cells is
This year, the Hamburg based life sciences company
Alembic Pharmaceutica
Since it’s an ingredient in so many foods, you h
In a world constantly in motion, Microbioz India r
The Advanced Medical Technology Association (AdvaMed) has made a detailed, nationwide covid-19 diagnostic supply registry to assist state and federal governments in their own wing responses. The national registry has been launched in partnership with 13 commercial diagnostics makers: Abbott, BD, bioMérieux, Bio-Rad, Beckman Coulter, Cepheid, Hologic, Ortho Clinical Diagnostics, Qiagen, Roche Diagnostics, Sekisui Diagnostics, Siemens Healthineers, along with Thermo Fisher Scientific. The registry’s first publicly published data set demonstrates that since the beginning of the pandemic, more than 65 million tests are manufactured and shipped nationwide, with evaluation shipments currently topping 800,000 daily.
“It is absolutely crucial to our country’s health and financial recovery that we have sufficient supplies to examine everybody who needs it, and, as important, to know where these supplies are so we can get them where they’re most needed,” says Scott Whitaker, president and CEO of AdvaMed. “This national registry is going to be a crucial instrument for national and state authorities as they work to protect both the patients and health care providers and move to reopen the US economy”
The registry will compile information from diagnostic companies along with publicly accessible data on daily tests performed to make a centralized and standardized covid-19 diagnostic distribution registry. The registry will provide weekly say – and – national-level updates on the number of molecular, antigen, and serology (antibody) tests shipped in america.
AdvaMed’s registry can help streamline communications and information sharing between diagnostic businesses and federal and state authorities in addition to standardize test supply reporting. It is going to also facilitate cooperation with labs and other public health stakeholders to optimize access to all platforms of covid-19 testing so that any prospective shortages are identified and handled quickly.
For more information, visit AdvaMed.
Featured image: Colorized scanning electron micrograph of an apoptotic cell (purple) heavily infected with SARS-COV-2 virus particles (yellow), isolated from a patient sample. Image captured at the NIAID Integrated Research Facility (IRF) in Fort Detrick, Maryland. Credit: NIAID.
